Abstract
Heart failure (HF), the final stage of pathological cardiac hypertrophy, is a major cause of hospitalization and mortality. The role of inflammation in the pathogenesis of HF has been extensively studied, with great emphasis on proinflammatory cytokines. Yet, clinical trials targeting these cytokines failed to become a credible therapeutic strategy for HF. More recent studies are increasingly highlighting an active role for T cells in the progression of HF pathology. As a result, a number of novel immunotherapy strategies are emerging for the treatment of HF and other cardiovascular diseases, via the targeting of adaptive immunity. Here we provide an overview of the background, details, and expected outcomes of these attempts.
| Original language | English |
|---|---|
| Journal | Journal of Leukocyte Biology |
| DOIs | |
| Publication status | E-pub ahead of print - Dec 19 2017 |
Fingerprint
Keywords
- Journal Article
- Review
Cite this
Immunotherapy for cardiovascular disease. / Martini, Elisa; Stirparo, Giuliano Giuseppe; Kallikourdis, Marinos.
In: Journal of Leukocyte Biology, 19.12.2017.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Immunotherapy for cardiovascular disease
AU - Martini, Elisa
AU - Stirparo, Giuliano Giuseppe
AU - Kallikourdis, Marinos
N1 - ©2017 Society for Leukocyte Biology.
PY - 2017/12/19
Y1 - 2017/12/19
N2 - Heart failure (HF), the final stage of pathological cardiac hypertrophy, is a major cause of hospitalization and mortality. The role of inflammation in the pathogenesis of HF has been extensively studied, with great emphasis on proinflammatory cytokines. Yet, clinical trials targeting these cytokines failed to become a credible therapeutic strategy for HF. More recent studies are increasingly highlighting an active role for T cells in the progression of HF pathology. As a result, a number of novel immunotherapy strategies are emerging for the treatment of HF and other cardiovascular diseases, via the targeting of adaptive immunity. Here we provide an overview of the background, details, and expected outcomes of these attempts.
AB - Heart failure (HF), the final stage of pathological cardiac hypertrophy, is a major cause of hospitalization and mortality. The role of inflammation in the pathogenesis of HF has been extensively studied, with great emphasis on proinflammatory cytokines. Yet, clinical trials targeting these cytokines failed to become a credible therapeutic strategy for HF. More recent studies are increasingly highlighting an active role for T cells in the progression of HF pathology. As a result, a number of novel immunotherapy strategies are emerging for the treatment of HF and other cardiovascular diseases, via the targeting of adaptive immunity. Here we provide an overview of the background, details, and expected outcomes of these attempts.
KW - Journal Article
KW - Review
U2 - 10.1002/JLB.5MR0717-306R
DO - 10.1002/JLB.5MR0717-306R
M3 - Review article
C2 - 29345361
JO - Journal of Leukocyte Biology
JF - Journal of Leukocyte Biology
SN - 0741-5400
ER -